Mizuho analyst Steven Valiquette raised the firm’s price target on Henry Schein (HSIC) to $81 from $74 and keeps a Neutral rating on the shares. Mizuho’s annual dental industry survey is more positive than prior years, the analyst tells investors in a research note. The firm upped targets in the dental group as part of its 2026 outlook.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSIC:
- Henry Schein enters exclusive distribution agreement with CytoChip
- Henry Schein appoints new CEO amid governance changes
- Henry Schein CEO Stanley Bergman to step down, Frederick Lowery to succeed
- Henry Schein Board Advances CEO Succession and Transition
- Henry Schein expects to appoint next CEO by mid-January 2026